Seekin Inc.’s cancer mutation detection kit Pancanseek for leukemia patients has received a CE-IVD mark, expanding the company’s reach in the testing space.
South Korea’s Legochem Bioscience Inc. inked a licensing deal with Amgen Inc. on Dec. 23 for five undisclosed antibody drug conjugate (ADC) targets worth up to ₩1.6 trillion (US$1.24 billion). Under the terms of the deal, Legochem will out-license global rights to Amgen for five undisclosed ADC targets and will receive an undisclosed up-front payment as well as development milestones and sales royalties. The companies did not disclose additional details.
Prenetics Global Ltd. agreed to acquire a majority stake in Act Genomics Holdings Co. Ltd. as part of a move to target the precision oncology market. Prenetics will issue 19.9 million class A ordinary shares and pay $20 million in cash to complete the acquisition.
Chinese authorities this year for the first time allowed access for complete U.S. Public Company Accounting Oversight Board (PCAOB) audit inspections and investigations of PCAOB-registered public accounting firms headquartered in China and Hong Kong, in accordance with U.S. securities law.
3D Medicines Inc. has raised HK$408 million (US$52.5 million) in a listing on the Hong Kong Stock Exchange. Its shares opened at HK$29 apiece, jumped by more than 20% by the middle of the day, and closed at HK$31.45 on the first trading day of Dec. 15.
Innovent Biologics Inc. has in-licensed LG Chem Ltd.’s tigulixostat (LC-350189), a late-stage non-purine xanthine oxidase inhibitor for managing chronic hyperuricemia in patients with gout, in a deal worth up to $95 million.
Medical technology company Synchron Inc. completed an AU$110 million (US$73.9 million) series C round that will allow the company to conduct a feasibility study and pivotal trial of its implantable brain computer interface that can interpret and stimulate parts of the brain.
Jiangsu Recbio Technology Co. Ltd. has received clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC-610, from the Food and Drug Administration of the Philippines. A phase I trial will be conducted in healthy volunteers.
Gaush Meditech Ltd. raised HK$672 million (US$86.4 million) on a Hong Kong Stock Exchange listing. The company plans to use 38.2% of the funds to improve its research and development capability and speed up the commercialization of its patents in two years.
Chaomu Technology (Beijing) Co. Ltd. has raised nearly ¥100 million (US$14 million) in a series A+ round to develop its ophthalmic medical devices. The proceeds from the financing will be used for the clinical trials of its electromodulation product for nystagmus and the development of implantable medical chips, as well as to speed up the development of products for myopia correction. Following the financing, Beijing-based Chaomu will expand to the global market by looking for collaborations with international institutions. It plans to obtain marketing approvals for its ophthalmic medical devices in the U.S. and Europe.